Medvi and Zepbound: Branded vs Compounded Access Explained

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Full head-to-head: PlexusDx vs MEDVi →

This is an independent editorial review. PlexusDx has no commercial relationship with Medvi, and no affiliate links or compensation are involved.

Searches for "Medvi Zepbound" usually come from one specific question: can you get brand-name Zepbound through Medvi, or does the program hand you a compounded tirzepatide instead? Zepbound is the branded, FDA-approved tirzepatide product, and how a telehealth service handles it says a lot about the model. This review maps where Zepbound sits inside Medvi’s offering, what that access costs, and the genetic variable no telehealth intake captures. Fair-balance editorial framing, not a buying recommendation. As of April 2026.

Where Zepbound sits inside Medvi’s program

Medvi (Medvi Wellness) runs a telehealth plus compounded-pharmacy model. Its core weight-management program dispenses compounded semaglutide and tirzepatide from licensed 503A compounding pharmacies rather than the branded products. Brand-name Zepbound lives on a separate track: as verified July 2026, Medvi offers branded Zepbound (and Wegovy) through a $99 membership plus the medication cost. That makes branded Zepbound a distinct, membership-based pathway from the no-membership compounded program — two different routes under one roof.

Compounded tirzepatide is not Zepbound. Compounded tirzepatide shares the same active ingredient as Zepbound, but it is a distinct, non-branded preparation produced by a compounding pharmacy — not the FDA-approved brand product and not a generic of it. If your goal is specifically the branded Zepbound pen, you are looking at Medvi’s membership pathway, not its flat-priced compounded line. Confirm current program structure on Medvi’s official website.

How a Zepbound-class prescription moves through Medvi

The mechanics mirror most telehealth GLP-1 programs. A patient completes an intake form covering weight, medical history, and current medications; a licensed clinician reviews it and, if eligibility criteria are met, issues a prescription; that prescription routes either to a retail pharmacy for an FDA-approved brand such as Zepbound or to a licensed 503A pharmacy for a compounded formulation; and ongoing telehealth follow-up supports dose titration and side-effect management. Provider type (physician versus NP or PA) and pharmacy partner vary by state and program tier.

What Zepbound access costs through Medvi

Medvi shows pricing after a short health questionnaire, and it is promotion-led. As captured July 2026, the compounded semaglutide line runs about $299 per month ongoing (after a $159 first-month promotional price), and compounded tirzepatide about $399 per month ongoing (after a $259 first month). Pricing is flat across dose, and multi-month prepaid bundles lower the effective monthly rate. The compounded program carries no membership fee and no separate consultation fee. Branded Wegovy or Zepbound are offered separately at a $99 membership plus the medication cost, so the branded Zepbound number depends on that pharmacy price rather than a flat compounded rate. Medvi also lists a dissolvable GLP-1 tablet with its price shown after intake. Verify everything at Medvi’s official website before committing — these figures move frequently.

The tirzepatide evidence base behind Zepbound

Zepbound’s pharmacology comes from its compound class, not from any telehealth brand. Tirzepatide is a GIP/GLP-1 dual agonist; semaglutide, liraglutide, and dulaglutide are GLP-1 receptor agonists. Key trial programs include SURMOUNT (tirzepatide for weight management, NEJM 2022), SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024), and STEP (semaglutide, NEJM 2021). Outcomes vary individually.

The genetic layer a Zepbound intake never reads

No telehealth intake — branded or compounded — reads the upstream genetic architecture that shapes a tirzepatide response. Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the GLP-1 receptor gene that is the direct target of these compounds), MC4R (a melanocortin receptor central to satiety), and TCF7L2 (a transcription factor tied to glucose homeostasis and GLP-1 secretion) describe the metabolic terrain a clinician prescribes into. These are pathway-level markers. They do not predict response to Zepbound or any specific compound, but they describe the biology underneath the prescription — context a questionnaire alone cannot supply.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What sets the PlexusDx approach apart is that upstream context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, GLP1R, MC4R, and TCF7L2 variants that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. That is the test before you invest approach: turning guesswork into an informed conversation with your provider.

Not affiliated: PlexusDx is not affiliated with Medvi and has no commercial relationship with the companies reviewed in this article.

Related reading on PlexusDx: Zepbound vs Trulicity, Zepbound For Hypertension, Zepbound Subscription, Zepbound vs Victoza.

Disclaimer: This article is educational. PlexusDx is not affiliated with Medvi and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols — this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach: see the Weight Management Protocols — semaglutide and tirzepatide with the genetic context telehealth programs skip. Or start upstream: take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions

Does Medvi prescribe brand-name Zepbound?

As verified July 2026, Medvi offers branded Zepbound and Wegovy through a $99 membership plus the medication cost, separate from its no-membership compounded program. That means brand-name Zepbound runs on a different, membership-based pathway. Confirm current availability and pricing directly on Medvi’s own site before enrolling.

Is Medvi’s compounded tirzepatide the same as Zepbound?

No. Compounded tirzepatide shares the same active ingredient as Zepbound but is a distinct, non-branded preparation from a licensed 503A pharmacy — not the FDA-approved brand product and not a generic. Quality, potency, and sourcing depend on the compounding pharmacy, so verify the pharmacy and provider credentials first.

What does Zepbound cost through Medvi’s model?

Branded Zepbound is offered at a $99 membership plus the medication cost, so the total depends on that pharmacy price. Medvi’s separate compounded tirzepatide line was about $399 per month ongoing as captured July 2026. Pricing shows after a health questionnaire and changes often, so verify on Medvi’s site.

How does the Precision Peptide Genetic Test relate to Zepbound’s pathway?

It does not predict how you will respond to Zepbound or any compound. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 and appetite biology — the upstream context that applies no matter which telehealth service or product delivers a tirzepatide prescription.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education